Analysts See $-0.13 EPS for Achillion Pharmaceuticals, Inc. (ACHN)

July 14, 2018 - By Elena Maslow

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) LogoInvestors sentiment decreased to 0.95 in 2018 Q1. Its down 1.13, from 2.08 in 2017Q4. It fall, as 26 investors sold Achillion Pharmaceuticals, Inc. shares while 29 reduced holdings. 17 funds opened positions while 35 raised stakes. 107.48 million shares or 2.61% less from 110.36 million shares in 2017Q4 were reported.
Artal Group invested 0.03% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). State Of Wisconsin Invest Board holds 85,000 shares. Bancorp Of America Corp De owns 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 364,183 shares. Proshare Advisors Lc reported 0% stake. C M Bidwell And Associate Ltd reported 20,825 shares stake. Great West Life Assurance Company Can holds 0% or 8,721 shares in its portfolio. Principal Fincl Grp Inc Inc stated it has 42,928 shares or 0% of all its holdings. The New York-based American Group Incorporated has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Schwab Charles Investment Mngmt invested in 700,848 shares or 0% of the stock. Arrowmark Colorado Ltd Co invested 0.03% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Spark Invest Mgmt Ltd Llc has invested 0.02% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Moreover, Baker Bros Advisors Lp has 0.09% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Dafna Management Lc has invested 1.57% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Switzerland-based Swiss Retail Bank has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Balyasny Asset Mgmt Ltd Liability Corporation reported 45,634 shares.

Analysts expect Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report $-0.13 EPS on August, 14.They anticipate $0.03 EPS change or 18.75 % from last quarter’s $-0.16 EPS. After having $-0.15 EPS previously, Achillion Pharmaceuticals, Inc.’s analysts see -13.33 % EPS growth. The stock increased 7.17% or $0.21 during the last trading session, reaching $3.14. About 3.48M shares traded or 210.42% up from the average. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 13.49% since July 14, 2017 and is downtrending. It has underperformed by 26.06% the S&P500.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Among 3 analysts covering Achillion Pharmaceuticals (NASDAQ:ACHN), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Achillion Pharmaceuticals had 4 analyst reports since February 8, 2018 according to SRatingsIntel. The stock has “Hold” rating by FBR Capital on Wednesday, February 7. Barclays Capital upgraded the stock to “Hold” rating in Monday, May 21 report. On Friday, February 23 the stock rating was maintained by FBR Capital with “Hold”.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $434.39 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

More notable recent Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news were published by: Nasdaq.com which released: “Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement …” on July 10, 2018, also Nasdaq.com with their article: “Achillion to Present at the 2018 JMP Securities Life Sciences Conference” published on June 14, 2018, Streetinsider.com published: “Achillion Pharma (ACHN) Commences Phase I First-in-Human Study of ACH-5548” on July 10, 2018. More interesting news about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) were released by: Fool.com and their article: “Better Buy: Inovio Pharmaceuticals, Inc. vs. Achillion Pharmaceuticals, Inc.” published on June 22, 2018 as well as Seekingalpha.com‘s news article titled: “Achillion Is A Worthwhile Biotech Speculation” with publication date: July 12, 2018.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.